Get the Stockscreener App
11.75
1.47%
0.17
Maplight Therapeutics Inc stock is traded at $11.75, with a volume of 451.47K.
It is up +1.47% in the last 24 hours and down -69.01% over the past month.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
See More
Previous Close:
$11.58
Open:
$12.04
24h Volume:
451.47K
Relative Volume:
0.61
Market Cap:
$532.81M
Revenue:
-
Net Income/Loss:
$-161.15M
P/E Ratio:
-3.1629
EPS:
-3.7149
Net Cash Flow:
$-138.61M
1W Performance:
-3.45%
1M Performance:
-69.01%
6M Performance:
-31.77%
1Y Performance:
+0.00%
1-Day Range:
$11.23
$12.25
1-Week Range:
$10.84
$12.52
52-Week Range:
$9.10
$40.43
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Name
Maplight Therapeutics Inc
Sector
Industry
Phone
650-839-4360
Address
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
11.75 | 516.03M | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Needham | Buy |
| Apr-07-26 | Initiated | TD Cowen | Buy |
| Mar-19-26 | Initiated | Canaccord Genuity | Buy |
| Nov-21-25 | Initiated | Jefferies | Buy |
| Nov-21-25 | Initiated | Leerink Partners | Outperform |
| Nov-21-25 | Initiated | Morgan Stanley | Overweight |
| Nov-21-25 | Initiated | Stifel | Buy |
View All
Maplight Therapeutics Inc Stock (MPLT) Latest News
Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta - Endpoints News
MapLight Therapeutics Announces $150 Million Private Placement Financing - marketscreener.com
MapLight bags USD 150m after muscarinic schizophrenia Phase II win - AllSci
MapLight Therapeutics, Inc. Stock 12‑Month Price Target Cut to $28.77, Implies 148% Upside - TradingView
Dividend HistoryMapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight Reports Positive Phase 2 Schizophrenia Data, Plans Phase 3 Trial - Minichart
MapLight Q2 Results: Net loss widens to $60.2M, cash runway extends to 2028 - scanx.trade
MapLight Therapeutics Secures $150 Million Through Private Stock Placement - Kalkine Media
MapLight Therapeutics Announces Q2 2026 Financial Results with Rising Losses and R&D Expenses - Kalkine Media
Form 8K MapLight Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
MapLight Therapeutics (Nasdaq: MPLT) boosts cash with $150M private deal - Stock Titan
MapLight Therapeutics 2Q 2026: Net loss $60.2M, EPS $(1.32) — 10-Q Summary - TradingView
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Maplight Therapeutics (NASDAQ:MPLT) Trading Up 6.4%Here's Why - MarketBeat
Latham Advises on MapLight Therapeutics’ US$150 Million Private Placement Financing - Latham & Watkins LLP
MapLight Therapeutics secures $150 million financing - thepharmaletter.com
Why is MapLight Therapeutics stock rallying today? - Investing.com
MapLight Therapeutics raises $150 million in private placement - Investing.com
Why is MapLight Therapeutics stock rallying today? By Investing.com - Investing.com South Africa
Zealand’s royalty deal; Khartis raises money for TED drug - Endpoints News
MapLight Therapeutics Launching $150 Million Private Placement Financing - marketscreener.com
MapLight Therapeutics stock jumps on $150M private placement By Investing.com - Investing.com South Africa
MapLight Therapeutics raises $150 million in private placement By Investing.com - Investing.com Canada
UBS Downgrades MapLight Therapeutics(MPLT.US) to Hold Rating, Cuts Target Price to $13 - Moomoo
MPLT Downgraded by UBS -- Price Target Lowered to $13.00 - GuruFocus
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap DownTime to Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating MapLight Therapeutics, Inc. (MPLT) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating MapLight Ther - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MapLight Therapeutics, Inc. (MPLT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 6.4%Time to Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating MapLight Therapeutics, Inc. (MPLT) And Encourages Investors to Connect - ACCESS Newswire
MapLight Therapeutics, Inc. (MPLT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
MapLight Therapeutics Inc (MPLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Bronstein, Gewirtz & Grossman, LLC Encourages MapLight Therapeutics, Inc. (MPLT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Maplight Therapeutics (NASDAQ:MPLT) Insider Sells 22,082 Shares of Stock - MarketBeat
Form 13D/A MapLight Therapeutics For: 3 August By Investing.com - Investing.com Canada
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law - TradingView
MPLT: MapLight Therapeutics, Inc.Balance Sheet - Zacks Investment Research
MapLight Therapeutics, Inc. (MPLT) stock price, news, quote and history - Yahoo Finance UK
Novo Holdings trims MapLight (MPLT) ownership below 5% after share sales - Stock Titan
Form 144 MAPLIGHT THERAPEUTICS For: 30 July By Investing.com - Investing.com Nigeria
Form 4 MapLight Therapeutics For: 30 July By Investing.com - Investing.com Nigeria
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 9.2%What's Next? - MarketBeat
MapLight Therapeutics director Troy Cox buys $148,702 in shares By Investing.com - Investing.com UK
Morgan Stanley Downgrades MapLight Therapeutics(MPLT.US) to Hold Rating, Cuts Target Price to $21 - Moomoo
ADAR1 Capital Management LLC Purchases New Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Shares Up 18.2% Following Insider Buying Activity - MarketBeat
MapLight Therapeutics Inc (MPLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
MapLight's schizophrenia candidate clears one bar but misses another - The Pharma Letter
MapLight Therapeutics stock crashes on Phase II schizophrenia data - Yahoo Finance
Maplight Therapeutics Inc Stock (MPLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):